Hierro en etapa preoperatoria y la transfusión en pacientes sometidas a histerectomía.
Saved in:
| Title: | Hierro en etapa preoperatoria y la transfusión en pacientes sometidas a histerectomía. |
|---|---|
| Alternate Title: | Iron in pre-operative stage and transfusion in patients undergoing hysterectomy. |
| Authors: | Campos-Aguirre, Esmeralda1 esmeralda.campos@imss.gob.mx, Bravo-Acevedo, Alicia2, Benitez-Arvizu, Gamaliel1 |
| Source: | Revista Medica del IMSS. 2023 Supplement 2, pS453-S459. 7p. |
| Subjects: | IRON supplements, BLOOD transfusion, HYSTERECTOMY, UTERINE fibroids, TREATMENT effectiveness, ANEMIA, UTERINE myomectomy |
| Abstract (English): | Background: The correction of preoperative anemia is part of the patient blood management program, in order to improve the patient's clinical results by reducing the number of transfusions in surgery. Uterine fibroids can cause anemia, so the application of iron before hysterectomy could reduce transfusion. Objective: To evaluate the impact of iron treatment in the preoperative stage on the need for transfusion in patients with anemia secondary to myomatosis in the trans and postoperative stage of hysterectomy. Material and methods: Patients with uterine myomatosis who presented with microcytic anemia in the preoperative stage were included; clinical records were reviewed, the clinical characteristics of the population were obtained; The patients were distributed into two study groups according to whether or not they had received iron treatment; the outcome variable was the transfusion of packed erythrocytes in the first 7 days after surgery. Results: 134 patients were included, with a median fibroid size of 4 cm. 21 (15.6%) patients used iron. Patients who used iron had a relative risk (RR): 0.36 (95%CI: 0.12-1.07). Delta hemoglobin < 1 g/dL, RR: 1.59 (95%CI: 0.94-2.67). Uterine fibroid size > 5cm had a RR of 1.96 (95%CI: 1.25-3.05). Conclusion: Treatment with iron in the pre-surgical stage showed a tendency to protect transfusions in the trans and post-surgical stage. The main factor related to transfusion was fibroid size > 5 cm. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción: la corrección de la anemia preoperatoria parte del programa de manejo hemático del paciente, a fin de mejorar sus resultados clínicos disminuyendo la cantidad de transfusiones en cirugía. La miomatosis uterina puede cursar con anemia, por lo que la aplicación de hierro antes de la histerectomía podría disminuir la transfusión. Objetivo: evaluar el impacto del tratamiento con hierro en la etapa prequirúrgica sobre la necesidad de transfusión en pacientes con anemia secundaria a miomatosis en la etapa trans y posoperatoria de histerectomía. Material y métodos: se incluyeron pacientes con miomatosis uterina que cursaron con anemia microcítica en la etapa preoperatoria; se realizó revisión de los expedientes clínicos y se obtuvieron las características clínicas de la población. Las pacientes se distribuyeron en dos grupos de estudio de acuerdo con el antecedente de haber recibido o no tratamiento con hierro. La variable de desenlace fue la transfusión de concentrados eritrocitarios en los primeros siete días a partir de la cirugía. Resultados: se incluyeron 134 pacientes, 21 (15.6%) utilizaron hierro. Las pacientes que utilizaron hierro tuvieron un riesgo relativo (RR) de 0.36 (IC95%: 0.12-1.07) para transfusión. La delta de hemoglobina < 1 g/dL tuvo un RR: 1.59 (IC95%: 0.94-2.67). El tamaño de mioma > 5 cm tuvo un RR: 1.96 (IC95%: 1.25-3.05). Conclusión: el tratamiento con hierro en etapa prequirúrgica mostró tendencia a protección para transfusiones en etapa trans y posquirúrgica. El principal factor relacionado para transfusión fue el tamaño del mioma > 5 cm. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 193079921 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Hierro en etapa preoperatoria y la transfusión en pacientes sometidas a histerectomía. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Iron in pre-operative stage and transfusion in patients undergoing hysterectomy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Campos-Aguirre%2C+Esmeralda%22">Campos-Aguirre, Esmeralda</searchLink><relatesTo>1</relatesTo><i> esmeralda.campos@imss.gob.mx</i><br /><searchLink fieldCode="AR" term="%22Bravo-Acevedo%2C+Alicia%22">Bravo-Acevedo, Alicia</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Benitez-Arvizu%2C+Gamaliel%22">Benitez-Arvizu, Gamaliel</searchLink><relatesTo>1</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Medica+del+IMSS%22">Revista Medica del IMSS</searchLink>. 2023 Supplement 2, pS453-S459. 7p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22IRON+supplements%22">IRON supplements</searchLink><br /><searchLink fieldCode="DE" term="%22BLOOD+transfusion%22">BLOOD transfusion</searchLink><br /><searchLink fieldCode="DE" term="%22HYSTERECTOMY%22">HYSTERECTOMY</searchLink><br /><searchLink fieldCode="DE" term="%22UTERINE+fibroids%22">UTERINE fibroids</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22ANEMIA%22">ANEMIA</searchLink><br /><searchLink fieldCode="DE" term="%22UTERINE+myomectomy%22">UTERINE myomectomy</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Background: The correction of preoperative anemia is part of the patient blood management program, in order to improve the patient's clinical results by reducing the number of transfusions in surgery. Uterine fibroids can cause anemia, so the application of iron before hysterectomy could reduce transfusion. Objective: To evaluate the impact of iron treatment in the preoperative stage on the need for transfusion in patients with anemia secondary to myomatosis in the trans and postoperative stage of hysterectomy. Material and methods: Patients with uterine myomatosis who presented with microcytic anemia in the preoperative stage were included; clinical records were reviewed, the clinical characteristics of the population were obtained; The patients were distributed into two study groups according to whether or not they had received iron treatment; the outcome variable was the transfusion of packed erythrocytes in the first 7 days after surgery. Results: 134 patients were included, with a median fibroid size of 4 cm. 21 (15.6%) patients used iron. Patients who used iron had a relative risk (RR): 0.36 (95%CI: 0.12-1.07). Delta hemoglobin < 1 g/dL, RR: 1.59 (95%CI: 0.94-2.67). Uterine fibroid size > 5cm had a RR of 1.96 (95%CI: 1.25-3.05). Conclusion: Treatment with iron in the pre-surgical stage showed a tendency to protect transfusions in the trans and post-surgical stage. The main factor related to transfusion was fibroid size > 5 cm. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Introducción: la corrección de la anemia preoperatoria parte del programa de manejo hemático del paciente, a fin de mejorar sus resultados clínicos disminuyendo la cantidad de transfusiones en cirugía. La miomatosis uterina puede cursar con anemia, por lo que la aplicación de hierro antes de la histerectomía podría disminuir la transfusión. Objetivo: evaluar el impacto del tratamiento con hierro en la etapa prequirúrgica sobre la necesidad de transfusión en pacientes con anemia secundaria a miomatosis en la etapa trans y posoperatoria de histerectomía. Material y métodos: se incluyeron pacientes con miomatosis uterina que cursaron con anemia microcítica en la etapa preoperatoria; se realizó revisión de los expedientes clínicos y se obtuvieron las características clínicas de la población. Las pacientes se distribuyeron en dos grupos de estudio de acuerdo con el antecedente de haber recibido o no tratamiento con hierro. La variable de desenlace fue la transfusión de concentrados eritrocitarios en los primeros siete días a partir de la cirugía. Resultados: se incluyeron 134 pacientes, 21 (15.6%) utilizaron hierro. Las pacientes que utilizaron hierro tuvieron un riesgo relativo (RR) de 0.36 (IC95%: 0.12-1.07) para transfusión. La delta de hemoglobina < 1 g/dL tuvo un RR: 1.59 (IC95%: 0.94-2.67). El tamaño de mioma > 5 cm tuvo un RR: 1.96 (IC95%: 1.25-3.05). Conclusión: el tratamiento con hierro en etapa prequirúrgica mostró tendencia a protección para transfusiones en etapa trans y posquirúrgica. El principal factor relacionado para transfusión fue el tamaño del mioma > 5 cm. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=193079921 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.5281/zenodo.8319809 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 7 StartPage: S453 Subjects: – SubjectFull: IRON supplements Type: general – SubjectFull: BLOOD transfusion Type: general – SubjectFull: HYSTERECTOMY Type: general – SubjectFull: UTERINE fibroids Type: general – SubjectFull: TREATMENT effectiveness Type: general – SubjectFull: ANEMIA Type: general – SubjectFull: UTERINE myomectomy Type: general Titles: – TitleFull: Hierro en etapa preoperatoria y la transfusión en pacientes sometidas a histerectomía. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Campos-Aguirre, Esmeralda – PersonEntity: Name: NameFull: Bravo-Acevedo, Alicia – PersonEntity: Name: NameFull: Benitez-Arvizu, Gamaliel IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2023 Supplement 2 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 04435117 Titles: – TitleFull: Revista Medica del IMSS Type: main |
| ResultId | 1 |
